Kabra Drugs Limited (BOM:524322)
India
· Delayed Price · Currency is INR 24.91
+0.14 (0.57%)
At close: Apr 28, 2026
Kabra Drugs Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Revenue | 573.34 | - | - | - | - | - | Upgrade
|
| Cost of Revenue | 505.98 | - | - | - | - | - | Upgrade
|
| Gross Profit | 67.36 | - | - | - | - | - | Upgrade
|
| Selling, General & Admin | 14.34 | 7.55 | 4.55 | 2.64 | 1.2 | 0.7 | Upgrade
|
| Other Operating Expenses | 15.87 | 9.63 | 2.82 | 0.81 | 0.55 | 0.78 | Upgrade
|
| Operating Expenses | 30.54 | 17.25 | 7.36 | 3.44 | 1.84 | 1.79 | Upgrade
|
| Operating Income | 36.82 | -17.25 | -7.36 | -3.44 | -1.84 | -1.79 | Upgrade
|
| Interest Expense | -0.03 | - | - | - | - | - | Upgrade
|
| Interest & Investment Income | - | - | - | 0.06 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 10.19 | 6.4 | - | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | 46.99 | -10.85 | -7.36 | -3.38 | -1.84 | -1.79 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | -0.01 | -0.01 | Upgrade
|
| Pretax Income | 46.99 | -10.85 | -7.36 | -3.38 | -1.85 | -1.8 | Upgrade
|
| Income Tax Expense | 4.02 | 0.01 | - | - | - | - | Upgrade
|
| Net Income | 42.96 | -10.86 | -7.36 | -3.38 | -1.85 | -1.8 | Upgrade
|
| Net Income to Common | 42.96 | -10.86 | -7.36 | -3.38 | -1.85 | -1.8 | Upgrade
|
| Shares Outstanding (Basic) | 21 | 11 | 4 | 4 | 4 | 4 | Upgrade
|
| Shares Outstanding (Diluted) | 21 | 11 | 4 | 4 | 4 | 4 | Upgrade
|
| Shares Change (YoY) | 144.81% | 149.01% | - | - | - | - | Upgrade
|
| EPS (Basic) | 2.03 | -0.99 | -1.68 | -0.77 | -0.42 | -0.41 | Upgrade
|
| EPS (Diluted) | 2.03 | -0.99 | -1.68 | -0.77 | -0.42 | -0.41 | Upgrade
|
| Free Cash Flow | - | -47.58 | -2.09 | -3.54 | -1.34 | -2.49 | Upgrade
|
| Free Cash Flow Per Share | - | -4.35 | -0.47 | -0.81 | -0.30 | -0.57 | Upgrade
|
| Gross Margin | 11.75% | - | - | - | - | - | Upgrade
|
| Operating Margin | 6.42% | - | - | - | - | - | Upgrade
|
| Profit Margin | 7.49% | - | - | - | - | - | Upgrade
|
| EBITDA | 36.93 | -17.18 | - | -3.34 | -1.74 | -1.48 | Upgrade
|
| EBITDA Margin | 6.44% | - | - | - | - | - | Upgrade
|
| D&A For EBITDA | 0.11 | 0.07 | - | 0.1 | 0.1 | 0.31 | Upgrade
|
| EBIT | 36.82 | -17.25 | -7.36 | -3.44 | -1.84 | -1.79 | Upgrade
|
| EBIT Margin | 6.42% | - | - | - | - | - | Upgrade
|
| Effective Tax Rate | 8.56% | - | - | - | - | - | Upgrade
|
| Revenue as Reported | 583.53 | 6.4 | - | 0.06 | - | - | Upgrade
|
| Advertising Expenses | - | 0.17 | 0.19 | 0.09 | 0.07 | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.